"Mastocytosis, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.
| Descriptor ID |
D034721
|
| MeSH Number(s) |
C04.557.450.565.465.750 C20.543.520.350.750
|
| Concept/Terms |
Mastocytosis, Systemic- Mastocytosis, Systemic
- Mastocytoses, Systemic
- Systemic Mastocytoses
- Systemic Mastocytosis
- Systemic Mast-Cell Disease
- Mast-Cell Disease, Systemic
- Mast-Cell Diseases, Systemic
- Systemic Mast Cell Disease
- Systemic Mast-Cell Diseases
Aggressive Systemic Mastocytosis- Aggressive Systemic Mastocytosis
- Aggressive Systemic Mastocytoses
- Mastocytoses, Aggressive Systemic
- Mastocytosis, Aggressive Systemic
- Systemic Mastocytoses, Aggressive
- Systemic Mastocytosis, Aggressive
Indolent Systemic Mastocytosis- Indolent Systemic Mastocytosis
- Indolent Systemic Mastocytoses
- Mastocytoses, Indolent Systemic
- Mastocytosis, Indolent Systemic
- Systemic Mastocytoses, Indolent
- Systemic Mastocytosis, Indolent
|
Below are MeSH descriptors whose meaning is more general than "Mastocytosis, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Mastocytosis, Systemic".
This graph shows the total number of publications written about "Mastocytosis, Systemic" by people in this website by year, and whether "Mastocytosis, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 0 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 0 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mastocytosis, Systemic" by people in Profiles.
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun; 2(6):EVIDoa2200339.
-
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021 12; 27(12):2192-2199.
-
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
-
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity. Leuk Lymphoma. 2022 01; 63(1):235-238.
-
Avapritinib for Systemic Mastocytosis. Expert Rev Hematol. 2021 08; 14(8):687-696.
-
Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms. Ann Allergy Asthma Immunol. 2020 08; 125(2):219-221.
-
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019 08 13; 3(15):2264-2271.
-
Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. Exp Mol Pathol. 2019 06; 108:131-136.
-
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 12; 16(12):1500-1537.